Novo Nordisk A/S (0QIU.IL)
| Previous close | 913.75 |
| Open | 911.00 |
| Bid | 872.90 x 0 |
| Ask | 929.30 x 0 |
| Day's range | 880.00 - 918.30 |
| 52-week range | 86.66 - 932.00 |
| Volume | |
| Avg. volume | 1,003,638 |
| Market cap | 3.826T |
| Beta (5Y monthly) | 0.21 |
| PE ratio (TTM) | 61.31 |
| EPS (TTM) | 14.86 |
| Earnings date | 07 Aug 2024 |
| Forward dividend & yield | 7.08 (1.04%) |
| Ex-dividend date | 18 Aug 2023 |
| 1y target est | N/A |
ZacksPharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
Bayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.
GlobeNewswireNovo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 17 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiate
Zacks4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
